Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock
April 29 2019 - 4:19PM
Repligen Corporation (NASDAQ: RGEN) today announced that it has
commenced an underwritten public offering of $175,000,000 in shares
of its common stock. In addition, Repligen Corporation expects to
grant the underwriters a 30-day option to purchase up to an
additional $26,250,000 in shares of its common stock in connection
with the proposed public offering. All shares of common stock will
be offered by Repligen Corporation.
Repligen Corporation expects to use the net proceeds to fund the
cash portion of the purchase price for its previously announced
proposed acquisition of C Technologies, Inc. and for working
capital and other general corporate purposes.
J.P. Morgan Securities LLC and Stephens Inc. are acting as joint
book-running managers for the offering. Janney Montgomery Scott is
acting as lead manager for the offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed or as to the actual
size or terms of the offering.
These securities will be issued and sold pursuant to an
automatically effective shelf registration statement (including a
base prospectus) that was filed with the Securities and Exchange
Commission (“SEC”). A preliminary prospectus supplement relating to
this offering will be filed with the SEC. This press release shall
not constitute an offer to sell or a solicitation of an offer to
buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. A copy
of the prospectus supplement relating to the offering will be filed
with the SEC and may be obtained, when available, from J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)
803-9204, or by email
at prospectus-eq_fi@jpmchase.com and from Stephens Inc.,
ATTN: Equity Syndicate Desk, 111 Center Street, Little Rock, AR
72201, or by telephone at (800) 643-9691.
About Repligen Corporation Repligen Corporation
(NASDAQ:RGEN) is a global bioprocessing company that develops and
commercializes highly innovative products that deliver cost and
process efficiencies to biological drug manufacturers worldwide.
Our portfolio includes filtration products (including XCell™ ATF,
TangenX™ SIUS™ TFF and Spectrum KrosFlo™ TFF filters and systems),
chromatography products (OPUS® pre-packed columns, chromatography
resins, ELISA kits) and protein products (Protein A affinity
ligands including NGL Impact™-A, cell culture growth factors).
Our XCell™ ATF Systems, available in stainless steel and
single-use configurations, are used in perfusion processes to
continuously concentrate cells and increase product yield from a
bioreactor. Single-use SIUS™ TFF cassettes and hardware are used
for biologic drug concentration in downstream filtration processes.
KrosFlo™ TFF cartridges and systems are used in both upstream and
downstream filtration processes. Our innovative line of OPUS®
chromatography columns, used in bench-scale through
commercial-scale biologics purification, are delivered pre-packed
to our customers with their choice of affinity resin. Protein
A ligands and growth factor products that we produce are essential
components of Protein A affinity resins used in biologics
purification, and cell culture media used to accelerate cell growth
in a bioreactor. Repligen’s corporate headquarters are in Waltham,
MA (USA), with additional administrative and manufacturing
operations in Marlborough, MA, Rancho Dominguez, CA, Lund, Sweden
and Ravensburg, Germany.
Cautionary Language Concerning Forward-Looking
StatementsThis press release contains forward-looking
statements regarding our future business expectations, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release which are not strictly historical
statements, constitute forward-looking statements, including,
without limitation, statements regarding the size of the proposed
offering, completion of the proposed offering and the anticipated
use of proceeds of the proposed offering, constitute
forward-looking statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” “anticipate,” or “could”
and similar expressions. Such forward-looking statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those anticipated,
including, without limitation, uncertainties related to market
conditions and the completion of the public offering on the
anticipated terms or at all. These and other risks and
uncertainties are described in greater detail in the section
entitled "Risk Factors" in Repligen’s most recent Annual Report on
Form 10-K on file with the Securities and Exchange Commission and
the other reports that Repligen periodically files with the
Securities and Exchange Commission. Actual results may differ
materially from those Repligen contemplated by these
forward-looking statements. These forward looking statements
reflect management’s current views and Repligen does not undertake
to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the
date hereof except as required by law.
Source: Repligen Corporation Sondra Newman Senior Director
Investor Relations(781) 419-1881 snewman@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024